COUNTERPOINT: No, Biotech Isn't In A Bubble
This article was originally published in Scrip
Talk of a biotech bubble has been rampant since US Federal Reserve Chair Janet Yellen made comments last year about valuations in the industry. The argument that the biotech sector is currently in a bubble is an easy one to make – valuations have been high, the IPO window has been wide open and news of M&A has been in the headlines constantly. Now, more than two years into these plentiful times for biotech, many are wondering if the bubble will burst.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.